M. Kulyk & Associates’s Thermo Fisher Scientific TMO Stock Holding History

M. Kulyk & Associates’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-460	Closed	-$239K	–	108
2024 Q4	$239K	Buy	460 +6	+1%	+$3.3K	0.05%	92
2024 Q3	$281K	Sell	454 -24	-5%	-$14.2K	0.06%	94
2024 Q2	$264K	Sell	478 -48	-9%	-$27.5K	0.06%	92
2024 Q1	$306K	Buy	526 +3	+0.6%	+$1.68K	0.07%	85
2023 Q4	$278K	Hold	523	–	–	0.06%	87
2023 Q3	$265K	Sell	523 -53	-9%	-$28.2K	0.07%	82
2023 Q2	$301K	Buy	576 +17	+3%	+$9.17K	0.08%	86
2023 Q1	$322K	Buy	559 +18	+3%	+$10.1K	0.1%	85
2022 Q4	$298K	Hold	541	–	–	0.1%	81
2022 Q3	$274K	Buy	541 +24	+5%	+$13.4K	0.1%	84
2022 Q2	$281K	Sell	517 -91	-15%	-$50.1K	0.09%	82
2022 Q1	$359K	Buy	608 +78	+15%	+$44.8K	0.1%	80
2021 Q4	$354K	Hold	530	–	–	0.09%	68
2021 Q3	$303K	Hold	530	–	–	0.1%	60
2021 Q2	$267K	Hold	530	–	–	0.1%	58
2021 Q1	$242K	Buy	+530	New	+$253K	0.09%	65

Other funds holding TMO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

M. Kulyk & Associates's TMO Position: Q1 2025 in Review

M. Kulyk & Associates sold out of Thermo Fisher Scientific (TMO) in Q1 2025, closing a stake of 460 shares — an estimated $239K sold.

M. Kulyk & Associates first reported a position in TMO in Q1 2021 and held it in 16 quarters. The position peaked at $359K in Q1 2022. 2,578 funds tracked by Wall St. Rank hold TMO as of Q1 2025.

M. Kulyk & Associates reported no remaining Thermo Fisher Scientific position as of Q1 2025 after selling out during the quarter.
M. Kulyk & Associates sold 460 Thermo Fisher Scientific shares in Q1 2025, an estimated $239K.
M. Kulyk & Associates first reported a position in Thermo Fisher Scientific in Q1 2021 and held it in 16 quarters.
M. Kulyk & Associates's Thermo Fisher Scientific position peaked at $359K in Q1 2022.
2,578 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2025.

Based on M. Kulyk & Associates's 13F filing for Q1 2025, filed 6 May 2025.